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Abstract
Bladder cancer is the second most common genitourinary malignancy with urothelial
cancer comprising nearly 90% of primary bladder tumors. Urothelial carcinoma of the
urinary bladder is the fifth most common malignancy in the United States, with an
estimated 76,960 new cases and 163,900 deaths in 2016. Radical cystectomy with lymph
node dissection remains the standard treatment for patients with muscle-invasive
urothelial carcinoma of the bladder, and also for nonmuscle-invasive disease, refractory
to intravesical therapy. The current approaches to pelvic lymph node dissections are
based on the removal of lymph nodes most commonly harboring metastatic disease,
notably the external iliac, obturator, and hypogastric lymph nodes. The boundaries for a
standard pelvic lymph node dissection generally include the bifurcation of the common
iliac vessels superiorly and the genitofemoral nerve laterally. Extended pelvic lymph
node includes the removal of lymph nodes between the bifurcation of the common iliac
vessels and the level of the aortic bifurcation, sometimes including distal aortic and
caval nodes up to the level of the inferior mesenteric artery, as well as presacral nodes.
Extended and superextended dissection has been reported to be associated with supe-
rior survival outcome.
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1. Introduction
Bladder cancer is the second most common genitourinary malignancy with urothelial cell
carcinomas comprising nearly 90% of primary bladder tumors. Urothelial carcinoma of the
urinary bladder is the fifth most common malignancy in the United States, with an estimated
76,960 new cases and 163,900 deaths in 2016 [1]. Although up to 86% of patients present with
superficial or localized tumors, 20–40% present with, or progress to develop, invasive disease
that carries a significant increase in the likelihood of having occult metastases [2]. Standard
treatment of muscle invasive bladder cancer and refractory to intravesical chemotherapy in
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
patients with nonmuscle invasive bladder is still radical cystectomy with lymph node dissec-
tion. Patients with muscle invasive bladder cancer have approximately 25% lymph node
involvement during the radical cystectomy [3]; if lymph node involvement is observed,
10-year mortality rate can be up to 80% due to adjuvant chemotherapy [2, 3]. Although lymph
node involvement portends a relatively poor prognosis, some patients exhibit long-term sur-
vival following surgery, with or without systemic chemotherapy [4]. The current approaches to
pelvic lymph node dissections are based on the removal of lymph nodes most commonly
harboring metastatic disease, notably the external iliac, obturator, and hypogastric lymph
nodes. Standard pelvic lymph node dissection is described removing the lymph nodes includ-
ing bifurcation of the common iliac vessels superiorly and the genitofemoral nerve laterally.
And the limit of inferior and medial boundaries includes the obturator nerve, bladder, and
internal iliac vessels medially and the endopelvic fascia, circumflex iliac veins, and Cloquet’s
node inferiorly [5–8] (Figure 1). For the standard pathological evaluation of lymph nodes to
detect the presence of tumor cell after surgery, formalin fixation with hematoxylin and eosin
(H&E) staining of 5-μm thick sections of each node is done. After these evaluations, nearly
25% of the patients are found to be involved with tumor in the lymph nodes during the
cystectomy [9].
In the literature, the nomenclature of lymph node dissection has been variable and is defined
differently by urologists. Dangle et al. divided lymph node dissection into four groups catego-
rized as follows:
Figure 1. Regional lymph nodes of the urinary bladder. The true pelvis is the primary lymphatic drainage area for the
urinary bladder. The secondary drainage area superior to the true pelvis includes the common iliac nodes and all nodes
up to the level of the aortic bifurcation.
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1. Limited lymphadenectomy (removal of the external iliac and obturator lymph nodes).
2. Standard lymphadenectomy (limited lymphadenectomy plus removal of the internal iliac
lymph nodes).
3. Extended lymphadenectomy (standard lymphadenectomy plus removal of the common
iliac and presacral lymph nodes).
4. Super-extended lymphadenectomy (extended lymphadenectomy plus removal of any
additional lymph nodes above the aortic bifurcation) [10].
The boundaries of extended pelvic lymph node dissection generally include the removal of
lymph nodes superior to the bifurcation of the common iliac vessels, to the level of the aortic
bifurcation, sometimes including distal aortic and caval nodes up to the level of the inferior
mesenteric artery and presacral nodes [11]. Extended and superextended dissection has been
reported to be associated with superior survival outcome. The potential for meaningful bias,
however, prohibits drawing definite conclusions [12–14].
2. Lymphatic drainage of bladder
The bladder is an extraperitoneal muscular urine reservoir that lies behind the pubic symphy-
sis in the pelvis [15]. The lymphatic drainage of the bladder is into the obturator, external iliac,
internal iliac (hypogastric), and common iliac lymph nodes. As with any region of the body,
prior surgery may alter the lymphatic outflow of the region [16]. According to description of
Leadbetter and Cooper in 1950, the lymphatic drainage of the bladder can be divided into six
groups anatomically:
1. The visceral lymphatic plexus is located into the bladder wall, initiating inside the sub-
mucosa and extending into the muscular layer of bladder.
2. The intercalated lymph nodes that are located in the juxtavesical lymph nodes within the
perivesical fat align into anterior, lateral, and posterior groups.
3. The pelvic collecting lymph nodes that drains medial side of the external iliac and hypo-
gastric lymph nodes.
4. Regional pelvic lymph nodes that drains the external iliac, hypogastric, and presacral
lymph node groups.
5. Lymphatic vessels that drains the regional pelvic lymph nodes.
6. Common iliac lymph nodes around the common iliac vessels [17].
The primary drainage of the bladder initiate from the external and internal iliac and obturator
lymph nodes, secondary drainage continues from the common iliac lymph nodes, and tertiary
drainage to the presacral nodes is from the trigone and posterior wall of the bladder [18].
Remarkably, a researcher from Mansoura supported the importance of the endopelvic that
includes obturator and internal iliac lymph nodes as sentinels for lymphatic drainage of the
bladder [19] (Figure 1).
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3. The frequency of lymph node involvement in muscle invasive bladder
cancer
Radical cystectomy with pelvic lymph node dissection remains the standard of care for
patients with muscle-invasive urothelial cancer of the bladder and select patients with high-
risk in nonmuscle-invasive bladder cancer. Approximately, 25% of patients with muscle-inva-
sive bladder cancer have lymph node metastases at radical cystectomy, with 45% of patients
with T3 or T4 disease, harboring nodal disease [19]. Steven and Poulsen [20] showed that 34%
of their patients with lymph node-positive disease were positive in lymph nodes that are not
usually included in standard lymphadenectomy. A study of autopsy including 1933 patients
showed that the incidence of pelvic and retroperitoneal lymph node metastasis is 25% in 98
patients with bladder cancer [21]. Contemporary series supported that lymph node metastasis
is observed in 18–24% of patients with bladder cancer [22, 23].
4. The importance of the number of positive lymph nodes
Lymph node positivity is a critical factor for disease-specific survival and a primary determi-
nant of therapeutic course following surgery. Multi-institutional series of patients treated with
radical cystectomy have shown that approximately 80% of patients with pathologic node
positive disease experience disease recurrence, compared with 30% of patients with
extravesical disease and pathologically negative lymph node [24–26]. Patients with regional
lymph node metastasis at the time of cystectomy are at considerable risk for disease relapse
and cumulative probability of survival for these patients’ remains at 5–30% [27]. There is an
increasing perception that extensive pelvic lymph node dissection is an important therapeutic
measure associated with improvement in cancer-specific survival in both lymph node-negative
and lymph node-positive patients [19, 28]. Honma et al. reported that patients with less than
four positive nodes had a statistically significant survival advantage compared with four or
more positive nodes, and the number of nodes removed has a significant impact on disease-
specific survival in node-positive patients. The removal of 13 or more nodes had a survival
benefit even in the node-positive patients [29]. If pelvic nodal involvement is proven, it should
be considered a manifestation of a systemic disease. However, the independent value of pelvic
lymph node dissection for survival in patients with bladder cancer remains controversial,
although it has been demonstrated that pelvic lymph node dissection cures some node-positive
patients [30].
Lymph node mapping studies show a significant percentage of metastases in lymph node-
positive patients occurring above the common iliac bifurcation [11, 18]. Lymph node-positive
patients with standard lymphadenectomy had significantly worse 5-year disease-free survival
compared with lymph node-positive patients who underwent extended lymphadenectomy,
and extended lymphadenectomy was an independent prognostic factor for disease-free sur-
vival [31]. Tarin et al. reported that number of positive lymph nodes was significantly associ-
ated with cancer-specific survival, whereas location of the positive node and lymph node
density were not. A total of 25% of patients with pN3 disease were recurrence-free at 5 year,
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which is not significantly different from patients with pN1 or pN2 disease [32]. Prior to the
practice of pelvic lymph node dissection, series reported dismal 5-year survival rates of 4–7%
in lymph node-positive patients [33–35]. Skinner reported a 36% improvement of 5-year
survival in bladder cancer patients with limited nodal disease undergoing bilateral pelvic
lymph node dissection at the time of cystectomy. Skinner concluded that a “meticulous” pelvic
lymph node dissection could provide cure and control of pelvic disease in some patients with
regional lymph node metastases without increasing the morbidity [36]. Knowledge of lymph
node status is important because it influences patient counseling and, more importantly,
clinical decision-making regarding follow-up scheduling and adjuvant chemotherapy [37].
The study of International Bladder Cancer Nomogram Consortium analyzed 9064 patients
who underwent radical cystectomy and lymphadenectomy for bladder cancer and reported
that 1550 patients treated with surgery alone have lymph node-positive disease. As the result
of this study, the authors have developed an international bladder cancer nomogram. The aim
of the nomogram is using information on patient age, sex, and time from diagnosis to surgery,
pathologic tumor stage and grade, tumor histological subtype, and regional lymph node status
to predict recurrence risk in patients with bladder cancer after surgery. Following this study, a
lot of nomogram series were published that include either total number of lymph nodes
removed, number of positive lymph nodes, or lymph node density, and finally, node parame-
ters placed in the final nomogram model [38].
Although lymph node metastasis is related to a relatively poor prognosis, some patients prove
long-term survival after surgery, with or without systemic chemotherapy. Because of the
different prognostic factors, stratification of lymph node-positive patients is needed to obtain
more individualized risk estimations. Although some studies have reported several prognostic
factors for lymph node-positive patients, predictive factors for survival in lymph node-positive
patients have not been controversial [39].
5. The importance of the size of lymph nodes (extra capsular invasion of
tumor, tumor burden, and lymphovascular invasion)
The extent of nodal involvement, or tumor burden, has also been reported as an independent
prognostic factor for survival in patients with bladder cancer [40]. Several recent studies have
also shown the prognostic influence of the degree of lymph node positivity on survival rates
[25, 41, 42]. The presence of tumor cells in the endothelium-lined space is defined as
lymphovascular invasion. The prognostic value of lymphovascular invasion is controversial in
bladder cancer [43, 44]. Some studies reported that lymphovascular invasion was present in 36%
of all the specimens in patients presenting with higher chances of metastatic disease [3, 45]. Quek
et al. found a statistical correlation between lymphovascular invasion and positive surgical
margins, high pathological stages, older patients, and female gender. Ten-year survival was
lower in patients with lymphovascular invasion than patients without lymphovascular invasion
(43 vs. 18%) [3]. Similarly, Lotan concluded in his study that lymphovascular invasion was an
independent predictor of recurrence and decreased disease-specific and overall survival in
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lymph node-negative patients. Blood vessel invasion of tumor cells of 22 patients who had a 5-
year survival of 29% [44]. In another study, 5-year survival is estimated in 56% of the 347 patients
without lymphovascular invasion (p = 0.0011). Significantly higher 5-year survival was demon-
strated for the 259 patients without lymphatic invasion compared to 110 with lymphatic invasion
(61 vs. 39%, p < 0.0000). Prognosis was significantly worse in patients with perineural invasion
compared with without perineural invasion (44 vs. 56%, p = 0.0007) [46].
6. The importance of number of removed lymph nodes
It is common knowledge that removing more nodes can improve survival. In an effort to
reduce understaging and maximize survival, many studies have tried to establish a minimum
number of lymph nodes needed to be taken at the time of radical cystectomy [40, 47, 48].
Several studies have indicated that the number of lymph nodes removed is a prognostic factor
in bladder cancer patients [7, 46, 47]. Researchers have tried to identify the minimum necessary
number of lymph nodes needed to be removed at radical cystectomy. However, the analysis of
a large tertiary care center’s database revealed that the probability of survival continues to rise
as the number of lymph nodes removed increases and that no minimum number of lymph
nodes can be determined [48]. Although several groups defined a minimum number of lymph
nodes to be removed to confer a survival benefit [40, 49], Koppie et al. reported that the
probability of survival rises as the number of lymph node removed increases [48]. Herr
reported in his study that lymph node-negative patients have increased survival and corre-
lated with the number of nodes removed, regardless of the stage of the tumor. As a result of
this study, the authors advised a minimum of nine lymph nodes should be removed [42].
Stein et al. [41] demonstrated that patients with 15 or more nodes removed had better recur-
rence-free survival than did those with less than 15 nodes removed. Leissner reported in his
study that adjuvant chemotherapy has positive effects on survival for lymph node-positive
patients or with extravesical disease, if 16 nodes were removed. Moreover, when lymph node
positivity is observed, survival increases, if the number of lymph node-positive was ≤5 [44].
Konety et al. [47] reported decreased risk of mortality when 10–14 lymph nodes were
removed. The Southwest Oncology Group study 8710 showed that the survival advantage
conferred by the removal of 10 or more nodes was found even in node-negative patients [50].
Fleischmann et al. performed only standard lymphadenectomy and removed a mean of 23
pelvic lymph nodes. But when patients were divided into quartiles by the number of nodes
examined, researchers could not find any significant differences in recurrence-free and overall
survival rates [51].
7. Factors that affect the number of removed lymph nodes in cystectomy
Different factors affect the actual number of lymph nodes removed and/or examined. A lot
of studies about the number of lymphadenectomy is high, but all have the limitations of retro-
spective studies, and the boundaries of lymphadenectomywere variable and themean numbers
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of removed nodeswere different. Because of the different surgeons andpathologists, the number
of removed lymphnodes and evaluated number of lymphnode and detected positive number of
lymph nodes may vary [52]. In the surgical series, the number of retrieved lymph nodes can be
influenced bymany factors, including the extent of pelvic lymph node dissection, intraoperative
decisions regarding the amount of tissue to removewithin each region of the pelvic lymph node,
surgeon’s experience, and presentation of pathologic specimens [53].
8. What should be the limit in pelvic lymph node dissection?
There still exists no consensus about the optimal boundaries of lymph node dissection, the
number of removed lymph nodes, and procedure’s prognostic and therapeutic role for patients
who underwent radical cystectomy for muscle-invasive bladder cancer, although the impor-
tance of lymph node status is proven for treatment of the bladder cancer [18, 49]. The histo-
pathological results and the extent of lymph node removal have significance as prognostic
criteria and thus as indicators for adjuvant therapy [8, 19, 28].
Nowadays, the European Association of Urology and the American Urological Association
guidelines could not advise clear recommendations about the boundaries of lymphadenectomy
and the number of removed lymph nodes [54]. The International Consultation on Urological
Diseases 2012 guidelines recommend the removal of all lymphatic tissue around the common
iliac, external iliac, internal iliac, and obturator group bilaterally because one-third of all positive
nodes are located around the common iliac artery [55].
Poulsen et al. [6] observed that extending the pelvic lymph node dissection to the bifurcation of
the aorta improved survival in patients with organ-confined (pT3a or less) disease.
Bi et al. reported a meta-analysis of six studies. They compared patients who underwent
extended lymph node dissection with nonextended lamp node dissection. They reported that
extended lymph node dissection have better recurrent-free survival than patients who
underwent nonextended lymph node dissection. And also, in a subgroup analysis, they showed
that patient who underwent extended lymph node dissection have better recurrent-free sur-
vival than nonextended patients in both patients with lymph node positive and negative [56].
Crozier reported that nonurothelial cancers are more advanced tumors than urothelial cancers
at the time of diagnosis. According to their results, more aggressive surgical treatment must be
performed for patients with nonurothelial muscle invasive cancer. Because of the potential
survival benefits for these patients, they recommend standard extended lymphadenectomy in
patients diagnosed with nonurothelial muscle invasive cancer [57].
At present, the limitation of exact boundaries of pelvic lymph node dissection remains contro-
versial both in the literature and in the guidelines [58]. It is obvious that a pelvic lymph node
dissection must be performed during cystectomy; however, in some studies, pelvic lymph
node dissection was not performed in 8, 11, and 60% of patients [59–61]. On the other hand,
in another recent SEER analysis performed between 1992 and 2003, 3603 cystectomies were
analyzed. In this study, including the hospitals, cystectomies were divided into groups
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according to the number of lymph nodes removed. The authors demonstrated that only 0–4
nodes were removed in 88.9% of patients in low-node count hospitals and 52.8% of cases in the
high-node count hospitals; likewise, 10–14 nodes were removed in 7.2% in low-node count
hospitals and 14.2% of patients in the medium- and high-node count hospitals [61].
9. Morbidity and mortality of pelvic lymph node dissection
Cystectomy is a one of major surgical procedure among urological operations with potential
complications often related to the urinary diversion. However, a pelvic lymph node dissection
does not have any effect on overall morbidity; it can increase operation time and sometimes
facilitate the execution of the cystectomy. The different parameters may affect the morbidity
related to pelvic lymph node dissection. Especially, in experienced hands, removing of pelvic
lymph node did not increase operative morbidity and using the anatomical approach may
decrease perioperative complications and perioperative mortality [62]. Moreover, increasing
the number of nodes removed did not increase morbidity. Some complications related to
lymphadenectomy, such as lymphoceles and lymphoedemas, were reported in 2% of patients
with<16 lymph nodes removed and 1%with 16 nodes removed [63]. As a result, pelvic lymph
node dissection is recommended if patients have no absolute contraindication and fit enough
to undergo a radical cystectomy, regardless of age and comorbidities.
10. Conclusion
Presence of lymph node metastasis is associated with poor recurrence-free and overall sur-
vival. Cystectomy with pelvic lymph node dissection is crucial for appropriate staging,
removal of micrometastatic disease, and identifying candidates for adjuvant chemotherapy
in patients with muscle invasive bladder cancer. Although there is still no consensus about
the limit of pelvic lymph node dissection, extended lymphadenectomy must performed in
patients with high risk of metastasis because of the potential survival benefit of the lymph-
adenectomy.
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